323 related articles for article (PubMed ID: 30923817)
1. Comparative Analysis of the Antiviral Effects Mediated by Type I and III Interferons in Hepatitis B Virus-Infected Hepatocytes.
Bockmann JH; Stadler D; Xia Y; Ko C; Wettengel JM; Schulze Zur Wiesch J; Dandri M; Protzer U
J Infect Dis; 2019 Jul; 220(4):567-577. PubMed ID: 30923817
[TBL] [Abstract][Full Text] [Related]
2. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
Mutz P; Metz P; Lempp FA; Bender S; Qu B; Schöneweis K; Seitz S; Tu T; Restuccia A; Frankish J; Dächert C; Schusser B; Koschny R; Polychronidis G; Schemmer P; Hoffmann K; Baumert TF; Binder M; Urban S; Bartenschlager R
Gastroenterology; 2018 May; 154(6):1791-1804.e22. PubMed ID: 29410097
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
[TBL] [Abstract][Full Text] [Related]
4. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication.
Wang YX; Niklasch M; Liu T; Wang Y; Shi B; Yuan W; Baumert TF; Yuan Z; Tong S; Nassal M; Wen YM
J Hepatol; 2020 May; 72(5):865-876. PubMed ID: 31863794
[TBL] [Abstract][Full Text] [Related]
5. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.
Lucifora J; Xia Y; Reisinger F; Zhang K; Stadler D; Cheng X; Sprinzl MF; Koppensteiner H; Makowska Z; Volz T; Remouchamps C; Chou WM; Thasler WE; Hüser N; Durantel D; Liang TJ; Münk C; Heim MH; Browning JL; Dejardin E; Dandri M; Schindler M; Heikenwalder M; Protzer U
Science; 2014 Mar; 343(6176):1221-8. PubMed ID: 24557838
[TBL] [Abstract][Full Text] [Related]
6. Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis.
Xia Y; Stadler D; Lucifora J; Reisinger F; Webb D; Hösel M; Michler T; Wisskirchen K; Cheng X; Zhang K; Chou WM; Wettengel JM; Malo A; Bohne F; Hoffmann D; Eyer F; Thimme R; Falk CS; Thasler WE; Heikenwalder M; Protzer U
Gastroenterology; 2016 Jan; 150(1):194-205. PubMed ID: 26416327
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus sensitivity to interferon-α in hepatocytes is more associated with cellular interferon response than with viral genotype.
Shen F; Li Y; Wang Y; Sozzi V; Revill PA; Liu J; Gao L; Yang G; Lu M; Sutter K; Dittmer U; Chen J; Yuan Z
Hepatology; 2018 Apr; 67(4):1237-1252. PubMed ID: 29059468
[TBL] [Abstract][Full Text] [Related]
8. HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes.
Alfaiate D; Lucifora J; Abeywickrama-Samarakoon N; Michelet M; Testoni B; Cortay JC; Sureau C; Zoulim F; Dény P; Durantel D
Antiviral Res; 2016 Dec; 136():19-31. PubMed ID: 27771387
[TBL] [Abstract][Full Text] [Related]
9. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus.
Isorce N; Testoni B; Locatelli M; Fresquet J; Rivoire M; Luangsay S; Zoulim F; Durantel D
Antiviral Res; 2016 Jun; 130():36-45. PubMed ID: 26971407
[TBL] [Abstract][Full Text] [Related]
10. Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B.
Goh ZY; Ren EC; Ko HL
World J Gastroenterol; 2021 Apr; 27(14):1369-1391. PubMed ID: 33911462
[TBL] [Abstract][Full Text] [Related]
11. Virology. Response to Comment on "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA".
Xia Y; Lucifora J; Reisinger F; Heikenwalder M; Protzer U
Science; 2014 Jun; 344(6189):1237. PubMed ID: 24926011
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
13. Cytidine deamination and cccDNA degradation: A new approach for curing HBV?
Ding S; Robek MD
Hepatology; 2014 Dec; 60(6):2118-21. PubMed ID: 25142126
[No Abstract] [Full Text] [Related]
14. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities.
Pagliaccetti NE; Chu EN; Bolen CR; Kleinstein SH; Robek MD
Virology; 2010 Jun; 401(2):197-206. PubMed ID: 20303135
[TBL] [Abstract][Full Text] [Related]
15. Virology. Comment on "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA".
Chisari FV; Mason WS; Seeger C
Science; 2014 Jun; 344(6189):1237. PubMed ID: 24926010
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.
Klumpp K; Shimada T; Allweiss L; Volz T; Lütgehetmann M; Hartman G; Flores OA; Lam AM; Dandri M
Gastroenterology; 2018 Feb; 154(3):652-662.e8. PubMed ID: 29079518
[TBL] [Abstract][Full Text] [Related]
17. Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment.
Shi H; Lu L; Zhang NP; Zhang SC; Shen XZ
World J Gastroenterol; 2012 Jul; 18(27):3617-22. PubMed ID: 22826629
[TBL] [Abstract][Full Text] [Related]
18. Interferon Alpha Induces Multiple Cellular Proteins That Coordinately Suppress Hepadnaviral Covalently Closed Circular DNA Transcription.
Cheng J; Zhao Q; Zhou Y; Tang L; Sheraz M; Chang J; Guo JT
J Virol; 2020 Aug; 94(17):. PubMed ID: 32581092
[TBL] [Abstract][Full Text] [Related]
19. Agonistic Activation of Cytosolic DNA Sensing Receptors in Woodchuck Hepatocyte Cultures and Liver for Inducing Antiviral Effects.
Suresh M; Li B; Huang X; Korolowicz KE; Murreddu MG; Gudima SO; Menne S
Front Immunol; 2021; 12():745802. PubMed ID: 34671360
[TBL] [Abstract][Full Text] [Related]
20. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
